Pre-filled Syringe
IBSA laboratories have developed the SINOVIAL gamma: a substitute for synovial fluid for infiltrative therapies in case of joint suffering or post-traumatic conditions. The pre-filled syringe technology simplifies the administration of the product, perfectly sterile, reducing the risk of errors, consequently improving safety.
SINOVIAL contains high-quality hyaluronic acid, obtained from bio-fermentation, to avoid the risk of allergies and other contamination. Each pre-filled syringe of the SINOVIAL Family allows a waste-free injection of the solution that is effective for up to 6 months, giving the product a long-term carry-over effect.
Want to know more about the technology?
Contact usWant to know who is IBSA?
DISCOVER MORESAFE AND CUTTING-EDGE TECHNOLOGY FOR THE OSTEOARTICULAR AREA
Do you want to know more?
Fill the form to contact us
IBSA Business Development
Since 2018, there has been a new Department in IBSA fully dedicated to Business Development, Licensing activities and CDMO projects. Licensing The Business Development Dept. is constantly looking for partners and international distributors for licensing agreements in countries where IBSA does not operate directly with its branches. IBSA is focused on strategic collaborations to achieve a common goal while sharing responsibilities, resources, risks and rewards. Close ties with local distributors are crucial for IBSA to grow at an international level. The Business Development Dept. also evaluates licensing-in opportunities for the expansion of product portfolio.